It has also been suggested that SGLT2 inhibitors might reduce liver fat in patients with type 2 diabetes, a condition linked to obesity and frequently associated with non‐alcoholic fatty liver disease.18, 19, 20. Here, SLC5A2 is linked to type 2 diabetes mellitus.